Functional Characterization of Human Cancer-Derived TRKB Mutations-Reference-Cited by-同舟云学术

Functional Characterization of Human Cancer-Derived TRKB Mutations

Published:2011-02-17 Issue:2 Volume:6 Page:e16871
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Geiger Thomas R.,Song Ji-Ying,Rosado Aranzazu,Peeper Daniel S.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Cancer genes and the pathways they control.;B Vogelstein;Nat Med,2004

2. A census of human cancer genes.;PA Futreal;Nat Rev Cancer,2004

3. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.;IB Weinstein;Clin Cancer Res,1997

4. Essential role for oncogenic Ras in tumour maintenance.;L Chin;Nature,1999

5. Reversible tumorigenesis by MYC in hematopoietic lineages.;DW Felsher;Mol Cell,1999

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NTRK Therapy among Different Types of Cancers, Review and Future Perspectives;International Journal of Molecular Sciences;2024-02-17

2. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib;Acta Pharmaceutica Sinica B;2024-02

3. Design of new small molecules derived from indolin-2-one as potent TRKs inhibitors using a computer-aided drug design approach;Journal of Biomolecular Structure and Dynamics;2024-01-13

4. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance;European Journal of Medicinal Chemistry;2024-01

5. Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma;Clinical and Translational Medicine;2023-11